Verified AI assistant and collaboration network for life-science research, products, and events · Est. 2026
The greatest frontier in human history isn't space. It's the human body.
科技改变世界，但真正改变人类命运的战场
在细胞里，在基因里，在每一个还未被治愈的疾病里
For too long, biological research has been locked behind paywalls, lab doors,
and decades of regulation that only the privileged few can navigate.
alsesAI tears down those walls — powered by artificial intelligence,
secured by blockchain, amplified by a worldwide community of minds.
Because the cure for cancer, Alzheimer's, and aging itself will not come from one lab.
It will emerge from all of us.
Humanity has conquered space, built superintelligent machines, and connected
eight billion minds. Yet disease, aging, and death still win — every single day.
Not because we lack intelligence. Because the knowledge is locked away.
alsesAI exists to change that equation forever.
Trained on PubMed, WHO databases and global patents. Answers in seconds.
基于 PubMed、WHO 数据库和全球专利库训练，秒级回答科研问题。
alsesAI is trained on PubMed, WHO international biological standards, NIBSC reference materials, and global patent databases. Ask anything about antibody standards, gene detection protocols, CRISPR methodologies, immunotherapy, or anti-aging science — and receive expert-level answers in seconds.alsesAI 基于 PubMed、WHO 国际生物标准、NIBSC 参考材料和全球专利数据库进行训练。无论是抗体标准、基因检测方案、CRISPR 方法、免疫疗法还是抗衰老科学，都能秒级给出专家级解答。
Blockchain IP Protection区块链知识产权保护▸
Every discovery timestamped. Every patent immutable. Your work is protected instantly.
每项发现即时加盖时间戳，每项专利不可篡改，您的成果立即受到保护。
Every research discovery or protocol you submit can be cryptographically timestamped to create a verifiable record of existence. Use it as supporting evidence for research logs and collaboration records; formal intellectual-property protection still requires appropriate legal review in your jurisdiction.您提交的科研发现或实验方案可通过密码学方式加盖时间戳，形成可验证的存在性记录。它可作为科研日志与协作记录的辅助证据；正式知识产权保护仍需结合所在司法辖区的法律审查。
🏆 Research Recognition🏆 科研影响力认可▸
Your scientific contributions, recognized and amplified on a global stage.
你的每一次科学贡献，都将在全球舞台上被看见和放大。
Every experiment published, every patent filed, every insight shared on alsesAI becomes part of your permanent scientific record — visible to collaborators, institutions, and industry leaders across the world. As your contributions grow, so does your influence. alsesAI tracks your academic footprint and connects your work to opportunities that transcend borders, disciplines, and time zones. The researchers who shape the future are those who choose to share it.在 alsesAI 上发布的每一个实验、申请的每一个专利、分享的每一个洞见，都将成为你永久科研档案的一部分，被全球的合作者、机构和行业领袖所见证。随着你的贡献不断增长，你的影响力也随之扩展。alsesAI 记录你的学术足迹，将你的研究成果与超越国界、学科和时区的机遇相连接。引领未来的研究者，正是那些选择分享的人。
Open Science Community开放科学社区▸
Share protocols, debate ideas, and collaborate with life-science researchers across borders.
分享实验方案，探讨科学想法，与不同地区的生命科学研究者协作。
Join a research community built to make biological discovery more open and easier to coordinate. Share experimental protocols, debate scientific ideas, collaborate across borders, and build on each other's work with clearer records and context.加入一个面向开放协作的科研社区，让生物科学发现更容易被记录、讨论和协同推进。分享实验方案、探讨科学想法、跨地区协作，并在更清晰的记录与上下文中延续彼此的工作。
I'm your AI research assistant for modern life science.
Ask about genes, proteins, variants, pathways, scientific research experiment, papers, targets, or biomarkers. I can reason across trusted sources such as PubMed, NCBI, UniProt, AlphaFold, ClinicalTrials.gov, ChEMBL, PubChem, GWAS Catalog, ClinVar, Reactome, STRING, and more.
alsesAI helps turn questions into evidence, evidence into insight, and insight into visible expertise, collaboration, and future scientific or commercial value.
Start with a real research question.
Enter to send · Shift+Enter for new line · AI may be inaccurate; verify scientific, safety, medical, and citation details.
We look forward to partnering with you. Reach a focused audience of biotech researchers, scientists, and innovators as alsesAI grows. Advertise your brand, products, or services where science meets technology.
If you run into login, AI response, file upload, profile, patent, or community issues, contact us and include a short description plus a screenshot if possible.
Programmable RNA-Guided Bridge Recombinase System for Seamless Large-Scale Genomic Insertion Without Double-Strand Break
By Andy · 2026-06-02
In the current (2025–2026) landscape of biotechnology and gene editing, there is a truly 'industry-shaking' patent breakthrough with immense commercial potential. It is not a small, incremental improvement, but rather a solution that completely resolves the biggest challenge CRISPR gene editing has faced for decades — how to safely, precisely, and reliably 'insert' large DNA fragments into living human cells.
This patented technology is led by the Massachusetts Institute of Technology (MIT) and the Feng Zhang team: an RNA-programmable 'Bridge Recombinase' system for precision in-situ insertion of large DNA fragments (Bridge Recombinase Mechanism / PLS System).
📄 Breakthrough Biotech Patent Analysis
1. General Information
Patent Title: Programmable RNA-Guided Bridge Recombinases for Large-Scale Genomic Insertion and Inversion
Core Inventors: Feng Zhang, et al. (MIT / Broad Institute)
Traditional CRISPR-Cas9 operates as "molecular scissors," excels at gene disruption (knock-out), but struggles with integration. Inserting long, functional donor DNA fragments (thousands of base pairs) yields low efficiency (typically
lt;5\%$) and triggers DNA damage responses (P53 pathway), leading to cell apoptosis or oncogenic mutations.
This patent bypasses the risky "cut-and-wait-for-repair" mechanism by introducing a fully programmable molecular system capable of precisely and safely writing large DNA fragments into the human genome without double-strand breaks.
3. Mechanism of Action
The technology utilizes an engineered Bridge Recombinase derived from insertion sequences (transposons). The mechanism comprises three core components guided by a bispecific non-coding RNA (Bridge RNA):
Bispecific Targeting (The Bridge RNA): The system utilizes a unique "Bridge RNA" featuring two structural loops: one loop physically tethers the target donor DNA fragment, while the second loop homing-in on the specific genomic locus within the patient's genome.
No-Cut Ligation: Guided by this RNA bridge, the recombinase aligns the donor and target DNA simultaneously, executing cleavage and recombination at the molecular level without generating double-strand breaks (DSBs). Large-scale gene integration is completed seamlessly.
4. Commercial and Clinical Value
Monogenic Disease Eradication: Instead of engineering thousands of distinct CRISPR scissors for individual patient mutations in disorders like Beta-Thalassemia or Duchenne Muscular Dystrophy (DMD), this technology allows the precise, single-step insertion of an entire, healthy wild-type gene, enabling a true "one-dose cure."
Disruption of CAR-T Manufacturing: Traditional CAR-T cell therapies rely on lentiviral or retroviral vectors to randomly insert exogenous genes, risking insertional mutagenesis and incurring high manufacturing costs. This system allows high-efficiency, non-viral insertion of massive CAR cassettes directly into genomic safe harbors (GSH), reducing production costs by over $80\%$.
High-Value Intellectual Property Wall: By securing the foundational logic of utilizing bispecific non-coding RNAs to guide recombinases for in situ macromolecular insertion, this patent establishes an immense commercial moat. Any biopharma firm seeking non-viral, non-cleavage-based gene integration therapeutics must license this underlying IP architecture.
